key: cord-0951140-ryjooo7g
authors: Resende, Paola Cristina; Gräf, Tiago; Paixão, Anna Carolina Dias; Appolinario, Luciana; Lopes, Renata Serrano; da Fonseca Mendonça, Ana Carolina; da Rocha, Alice Sampaio Barreto; Motta, Fernando Couto; Neto, Lidio Gonçalves Lima; Khouri, Ricardo; de Oliveira, Camila Indiani; Santos-Muccillo, Pedro; Bezerra, Joao Felipe; Teixeira, Dalane Loudal Florentino; Riediger, Irina; do Carmo Debur, Maria; Ribeiro-Rodrigues, Rodrigo; Leite, Anderson Brandao; do Santos, Cliomar Alves; Gregianini, Tatiana Schäffer; Fernandes, Sandra Bianchini; Bernardes, André Felipe Leal; Cavalcanti, Andrea Cony; Miyajima, Fábio; Sachhi, Claudio; Mattos, Tirza; da Costa, Cristiano Fernandes; Delatorre, Edson; Wallau, Gabriel L; Naveca, Felipe G; Bello, Gonzalo; Siqueira, Marilda Mendonça
title: A potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil
date: 2021-03-13
journal: bioRxiv
DOI: 10.1101/2021.03.12.434969
sha: b3ffb20ce28b19f2381b0cc9b817f80656d07ec6
doc_id: 951140
cord_uid: ryjooo7g

The SARS-CoV-2 epidemic in Brazil was dominated by two lineages designated as B.1.1.28 and B.1.1.33. Two SARS-CoV-2 variants harboring mutations at the receptor-binding domain of the Spike (S) protein, designated as lineages P.1 and P.2, evolved within lineage B.1.1.28 and are rapidly spreading in Brazil. Lineage P.1 is considered a Variant of Concern (VOC) because of the presence of multiple mutations in the S protein (including K417T, E484K, N501Y), while lineage P.2 only harbors mutation S:E484K and is considered a Variant of Interest (VOI). Here we report the identification of a new SARS-CoV-2 VOI within lineage B.1.1.33 that also harbors mutation S:E484K and was detected in Brazil between November 2020 and February 2021. This VOI displayed four non-synonymous lineage-defining mutations (NSP3:A1711V, NSP6:F36L, S:E484K, and NS7b:E33A) and was designated as lineage N.9. The VOI N.9 probably emerged in August 2020 and has spread across different Brazilian states from the Southeast, South, North and Northeast regions.

The SARS-CoV-2 epidemic in Brazil was dominated by two lineages designated as B. 1 Table 1 ). Mutational profile was investigated using the nextclade tool 

Nucleotide

Among the 35 genomes identified so far as VOI N.9, 10 Brazilian states were represented, suggesting that this lineage is already highly dispersed in the country. The VOI N. 

Oswaldo Cruz Institute, Fiocruz 2. Plataforma de Vigilância Molecular

Laboratório de Enfermidades Infecciosas Transmitidas por Vetores, Instituto Gonçalo Moniz

Laboratório Central de Saúde Pública do Estado do Alagoas

Fundação de Vigilância em Saúde do Amazonas

Centro de Ciências Exatas

Leônidas e Maria Deane Institute, Fiocruz 23. Laboratório de AIDS e Imunologia Molecular

Evolution and epidemic spread of SARS-CoV-2 in Brazil

Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 lineage B.1.1.33 during the early pandemic phase in Brazil

Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan

COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1. Research Square

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen)

Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Comprehensive mapping of mutations in the SARS

CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B

to Antibody Neutralization

The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape

This study was approved by the FIOCRUZ-IOC Ethics Committee (CAAE: 68118417.6.0000.5248 and 32333120.4.0000.5190) and the Brazilian Ministry of the Environment (MMA) SISGEN (A1767C3).The authors wish to thank all the health care workers and scientists who have worked hard to deal with this pandemic threat, the GISAID team, and all the EpiCoV database's submitters, GISAID acknowledgment table containing sequences used in this study is attached to this post (Appendix Table 2 ). We also appreciate the support of the Fiocruz COVID-19 Genomic Surveillance